Litigation Delays Rule

Branded pharmaceutical companies, medical groups or state regulators challenge the HHS policy on safety, statutory authority or patent-related grounds. The rule is not necessarily defeated, but court action slows implementation and keeps market access fragmented.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.